Agilent Technologies, Inc. $A Shares Newly Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Agilent Technologies, Inc. (NYSE:A) in the 3rd quarter, Holdings Channel reports. The fund purchased 86,339 shares of the medical research company’s stock, valued at approximately $14,877,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp grew its stake in Agilent Technologies by 0.7% during the second quarter. State Street Corp now owns 12,854,230 shares of the medical research company’s stock worth $1,710,658,000 after buying an additional 89,598 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Agilent Technologies by 2.7% during the second quarter. Wellington Management Group LLP now owns 7,454,686 shares of the medical research company’s stock worth $990,206,000 after buying an additional 198,253 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Agilent Technologies by 17.1% during the second quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company’s stock worth $930,957,000 after buying an additional 1,024,516 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Agilent Technologies by 87.4% in the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after acquiring an additional 2,440,360 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Agilent Technologies by 9.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,108,764 shares of the medical research company’s stock valued at $240,336,000 after acquiring an additional 185,223 shares during the last quarter.

Agilent Technologies Trading Up 2.2%

Shares of NYSE A opened at $175.73 on Wednesday. Agilent Technologies, Inc. has a 1-year low of $108.35 and a 1-year high of $182.99. The company has a market cap of $49.54 billion, a PE ratio of 34.59, a P/E/G ratio of 2.52 and a beta of 1.24. The company has a current ratio of 2.05, a quick ratio of 1.56 and a debt-to-equity ratio of 0.50. The company has a 50-day moving average of $164.81 and a two-hundred day moving average of $136.68.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The company had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. During the same period in the prior year, the business earned $1.37 earnings per share. Agilent Technologies’s quarterly revenue was up 8.1% on a year-over-year basis. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, equities analysts expect that Agilent Technologies, Inc. will post 6.20 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 28th. Shareholders of record on Tuesday, October 6th were issued a dividend of $0.2550 per share. The ex-dividend date of this dividend was Tuesday, October 6th. This represents a $1.02 annualized dividend and a yield of 0.6%. Agilent Technologies’s dividend payout ratio is currently 20.08%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, Director Mikael Dolsten sold 634 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $151.38, for a total value of $95,974.92. Following the transaction, the director directly owned 4,924 shares in the company, valued at approximately $745,395.12. This trade represents a 11.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Barclays boosted their target price on Agilent Technologies from $175.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Rothschild & Co Redburn raised their price target on Agilent Technologies from $160.00 to $180.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Weiss Ratings upgraded Agilent Technologies from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Deutsche Bank Aktiengesellschaft initiated coverage on Agilent Technologies in a research note on Monday, October 26th. They issued a “buy” rating and a $190.00 price objective on the stock. Finally, Morgan Stanley increased their target price on Agilent Technologies from $175.00 to $190.00 and gave the stock an “overweight” rating in a report on Tuesday, October 13th. Eighteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $181.45.

Agilent Technologies Company Profile

Agilent Technologies, Inc is a global provider of analytical laboratory instruments, software, services and consumables. The company serves customers in the pharmaceutical, biotechnology, chemical, food, environmental, energy and academic research sectors, as well as diagnostic and clinical laboratories.

Agilent’s offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic instruments, laboratory automation products, genomic and cell analysis solutions, and related software.